Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,001–1,100 of 1,640
Signaling Pathways Involved in Cognitive Enhancement
Nelson, T. J., Sun, M., & Alkon, D. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00002-4 · Cited by 8
Latagliata, E. C., Iacono, L. L., Chiacchierini, G., Sancandi, M., Rava, A., Oliva, V. N. L. D. S., & Puglisi‐Allegra, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00530 · Cited by 7
“The action of acute (single) administration is transient, and its effects on glutamate depend on blockade of GABA interneurons tonic firing (Duman and Aghajanian, 2012, 2014; Wohleb et al., 2017).”
BackgroundResearch Progress in the Pathogenesis of Post-stroke Depression
He, W., & Yan, Y. (2021) · Journal of Clinical and Nursing Research · doi:10.26689/jcnr.v5i2.1913 · Cited by 7
Gao, F., Liu, A., Qi, X., Wang, M., Chen, X., Wei, S., Gao, S., Sun, Y., Sun, P., Li, X., et al. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049374 · Cited by 7
“Consistent evidence from studies on the etiology and treatment of MDD are suggestive of the central role of homeostatic control of synaptic connections (Duman and Aghajanian, 2012; Duman et al., 2016).”
Réus, G. Z., Manosso, L. M., Arent, C. O., Borba, L. A., & Abelaira, H. M. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1570159x20666220329143804 · Cited by 7
The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments
Popoli, M., Ieraci, A., & Musazzi, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_5 · Cited by 9
The Role of Vesicle Release and Synaptic Transmission in Depression
Zhang, C., Zhu, L., Shi, H., & Zhu, L. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.10.001 · Cited by 9
Pereira, A. D. S., Miron, V. V., Castro, M. F. V., Bottari, N. B., Assmann, C. E., Nauderer, J. N., Bissacotti, B. F., Mostardeiro, V. B., Stefanello, N., Baldissarelli, J., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.111852 · Cited by 9
Wang, S., Xia, Z., Yang, S., Chen, W., Zhao, Y., Li, M., Tian, D., Pan, Y., Lin, X., Zhu, X., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16318 · Cited by 9
“In contrast, other critical brain regions involved in MDD, such as prefrontal cortex and hippocampus, exhibit reduced synaptic transmission and neuronal morphology atrophy (Belleau et al., 2019; Duman & Aghajanian, 2012; Ota & Duman, 2013).”
BackgroundThe Wnt signaling pathway in major depressive disorder: A systematic review of human studies
Sánchez-Ruiz, J. A., Treviño‐Alvarez, A. M., Zambrano-Lucio, M., Lozano-Díaz, S. T., Wang, N., Biernacka, J. M., Tye, S. J., & Barboza, A. B. C. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115983 · Cited by 13
Morozova, A. Y., Zubkov, E. A., Koshkin, F. A., Storozheva, Z. I., & Chekhonin, V. P. (2014) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-014-2338-y · Cited by 7
Sufka, K. J., & White, S. W. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.013 · Cited by 7
“A body of evidence argues that depression reflects stunted neurogenesis in homeostatic networks that respond to stress (Duman and Aghajanian, 2012; Eisch and Petrik, 2012).”
BackgroundSzabo, S. T., & Nemeroff, C. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00103-0 · Cited by 6
Neuroprotective roles of neurotrophic factors in depression
Groß, C., & Seroogy, K. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00007-0 · Cited by 11
Terauchi, A., Durlacher, E., Pitino, J. C., & Umemori, H. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001399 · Cited by 8
Che, Y.-X., Jin, X., Xiao, R.-H., Ming, Z., Ma, X., Guo, F., & Li, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00854-7 · Cited by 6
Hu, W., Liuyang, Z., Tian, Y., Liang, J., Zhang, X., Zhang, H., Wang, G., Huo, Y., Shentu, Y., Wang, J., et al. (2022) · EMBO Reports · doi:10.15252/embr.202254911 · Cited by 8
“Brain imaging and postmortem autopsy show a decreased hippocampal volume in major depression patients, accompanied by a reduction in dendritic arborization and spine density (Kempton et al , 2011; Duman & Aghajanian, 2012).”
Neurotrophic paths in the treatment of depression
Hayley, S. P., & Anisman, H. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130146 · Cited by 9
Xia, M., Liu, J., Mechelli, A., Sun, X., Ma, Q., Wang, X., Wei, D., Chen, Y., Liu, B., Huang, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.24.352153 · Cited by 7
Gold, P. W., & Wong, M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03019-8 · Cited by 7
“Mostmelancholia manifestations are partially or entirely corrected by effective antidepressant treatment [18, 31 – 33, 40, 44 – 46], including normalizing the following structures and functions.”
NRXN3-NLGN1 complex influences the development of depression induced by maternal separation in rats
Rong, Y., Yan, W., Gao, Z., Yang, Y., Xu, C., & Zhang, C. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149659 · Cited by 6
Jia, F., Chen, X., Wang, X., Quan, C., Ruan, J., Huang, Y., Fu, X., Wang, Y., Sun, H., Liu, L., et al. (2025) · Psychoradiology · doi:10.1093/psyrad/kkaf014 · Cited by 10
Zhang, Y., Guan, W., & Miao, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117085 · Cited by 6
Tsai, C.-C., Fan, C., Lin, C.-W., Bouakaz, A., & Yeh, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118373 · Cited by 8
Zhu, P., Luo, Y., Li, Y., Tang, J., Liu, L., Deng, Y., Li, J., Jiang, L. H., Yang, W., Xiao, Q., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03495-0 · Cited by 10
“Both clinical and basic studies have demonstrated that depression is associated with decreased neuronal synapses in the hippocampus and that antidepressants can block or reverse these neuronal de fi cits [15].”
Shi, Z., Luan, J., Zhang, Y., Wang, G., Mei, C., Chen, L., Zhou, W., Xiong, C., Huang, T., Zhan, J., et al. (2025) · Nutrients · doi:10.3390/nu17193037 · Cited by 14
“…adenosine neuromodulatory system are initially an adaptive response to homeostasis, but under chronic stress conditions, persistent changes in the adenosine neuromodulatory system can lead to synaptic dysfunction, which is considered to be the root cause of depressive-like behavior [109,119,120].”
Zhu, D., Wang, M., Liu, F., Zhan, S., Feng, Y., Li, C., Yi, Y., Li, C., Zhou, C., Zhang, Y., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106128 · Cited by 9
Zalsupindole: A Non-Hallucinogenic Psychoplastogen Advancing Psychedelic-Inspired Therapeutics
Salfiti, M., Kyriazis, M., & Mikellides, G. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00707 · Cited by 9
Bravi, B., Bollettini, I., Pasquasio, C. D., Falini, A., Colombo, C., Zanardi, R., Poletti, S., & Benedetti, F. (2022) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2022.111534 · Cited by 6
Saito-Takatsuji, H., Yoshitomi, Y., Yamamoto, R., Furuyama, T., Ishigaki, Y., Kato, N., Yonekura, H., & Ikeda, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043736 · Cited by 8
Hippocampal BAIAP2 prevents chronic mild stress-induced depression-like behaviors in mice
Fu, Y., Guo, X., Yang, R., Feng, H., Yin, X., Wang, S., Song, L., Wang, X., Zhao, P., Wang, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1192379 · Cited by 8
Cai, C.-Y., Liang, H., Zhou, T., Yang, C., Yin, J.-J., Yao, M.-H., Gu, Q., Liu, D., & Ni, H. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148480 · Cited by 6
Wei, L., Wang, T., Luo, M., Zhang, S., Lu, M., Zhou, X., Cheng, X., Wang, H., & Xu, D. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110814 · Cited by 7
Raouf, P., Shalchyan, V., & Rostami, R. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.106392 · Cited by 7
Glavonic, E., Dragić, M., Mitić, M., Aleksic, M., Lukić, I., Ivković, S., & Adžić, M. (2024) · Pharmaceuticals · doi:10.3390/ph17060669 · Cited by 7
“Canoni-cally, ketamine also upregulates BDNF expression and activates the mammalian target of rapamycin (mTOR) signaling cascade within these structures [39,42–44], thus affecting the molecular signals involved in fear extinction processes.”
BackgroundHuang, X., Zhu, Z., Du, M., Wu, C., Fu, J., Zhang, J., Tan, W., Wu, B., Liu, L., & Liao, Z. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08793-2 · Cited by 7
“…volumes of critical brain structures involved in cognitive regulation, specifically the prefrontal cortex and hippocampus (Price & Duman, 2020), marked by neuronal atrophy and synaptic inhibition in the medial prefrontal cortex and hippocampus (Duman & Aghajanian, 2012; Duman et al., 2016).”
BackgroundHuang, B., Li, X., Zheng, Y., Mai, Y., & Zhang, Z. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13736 · Cited by 8
“Esketamine administration can induce rapid synaptogenesis within hours (11).”
BackgroundHong, H., Gao, M., Zhou, M., Wang, A., Hua, R., Ma, Z., Wang, Y., Xu, Y., Bai, Y., Huang, G., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117304 · Cited by 7
Good, K., Kalani, L., Vincent, J. B., & Ausió, J. (2025) · Biochemistry and Cell Biology · doi:10.1139/bcb-2024-0237 · Cited by 7
Fang, D., Lü, J., Ran, H., He, Y., Zheng, G., Liu, S., Xiang, Y., Wang, X., Liu, X., Xiao, Y., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119946 · Cited by 8
The involvement of Notch1 signaling pathway in mid-aged female rats under chronic restraint stress
Shen, J., Lin, L., Liao, L., Liang, W., Yang, X., Lin, K., Ke, L. W., Zhang, L., Kang, J., Ding, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135313 · Cited by 7
Wang, Q., Cheng, L., Wu, B.-Y., Xu, P., Qiu, H.-Y., Wang, B., Yan, X.-J., & Chen, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1063722 · Cited by 8
Zhu, J., Guo, S., Hu, S., & Chen, Q. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114440 · Cited by 6
Marques, K. L., Moreira, M. L., Thiele, M. C. M., Cunha-Rodrigues, M. C., & Barradas, P. C. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114571 · Cited by 7
PGAM5 knockout causes depressive‐like behaviors in mice via ATP deficiency in the prefrontal cortex
Cui, W., Chen, C., Gong, L., Wen, J., Yang, S., Zheng, M., Gao, B., You, J., Lin, X., Hao, Y., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14377 · Cited by 9
Antidepressant effect and mechanism of TMP269 on stress-induced depressive-like behavior in mice
Meng, Y., Xiao, L., Liu, R., Du, J., Liu, N., Yu, J., Li, Y., & Lu, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116320 · Cited by 6
Zhao, H., Liang, B., Yu, L., & Xu, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4601 · Cited by 6
“The leading hypothesis on depression suggests that neuronal plasticity and impaired synaptic function are critical for mediating behavioral responses to anti-depressants (4,5).”
Efficacy of different doses of ketamine as a bolus in major depressive disorder.
Kheirkhah, F., Tayyebi, G., Rabiee, S. M., Moghadamnia, A. A., & Bijani, A. (2018) · PubMed Central · doi:10.22088/cjim.9.3.220 · Cited by 7
“Among other postsynaptic signaling pathways (36), the ketamine-induced synaptogenesis involves the inhibition of the eukaryotic elongation factor 2 (eEF2) kinase, leading to reduced eEF2 phosphorylation and subsequently increased BDNF translation (37).”
BackgroundSubanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats
Davis-Reyes, B. D., Smith, A. E., Xu, J., Cunningham, K. A., Zhou, J., & Anastasio, N. C. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000623 · Cited by 7
“, 2020), resulting in disinhibition of cortical pyramidal glutamatergic neurons and a ‘burst’ of downstream Glu (Duman and Aghajanian, 2012; Duman, 2018).”
BackgroundHøstmælingen, A., Ulvenes, P., Nissen‐Lie, H. A., Eielsen, M., & Wampold, B. E. (2022) · Journal of Counseling Psychology · doi:10.1037/cou0000572 · Cited by 6
RETRACTED: Exploring the role of astrocytic dysfunction and AQP4 in depression
Rana, T., Behl, T., Shamsuzzaman, M., Singh, S., Sharma, N., Sehgal, A., Alshahrani, A. M., Aldahish, A. A., Chidambaram, K., Dailah, H. G., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110359 · Cited by 9
RetractedYan, M., Fu, X., Ou, Y., Liu, F., Li, H., & Guo, W. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.897707 · Cited by 6
Yu, X., Zhong, K.-L., Chen, C., Fu, J., Chen, F., Zhou, H., Zhang, X., Kim, K., & Pan, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06464-x · Cited by 9
“…blockade increases glutamate transmission and stimulates mTOR signaling via the release of BDNF, which subsequently activates TrkB-Akt signaling (Duman and Aghajanian 2012), leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the…”
InfluentialThomas, R., Çetin, M., Baker, G. B., & Dursun, S. M. (2016) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20161027122045 · Cited by 8
“…M. Dursun4 Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(4):329-31 Editorial DOI: 10.5455/bcp.20161027122045 Duman & Aghajanian (2012) in Science called the use of esketamine as an antidepressant in psychiatry “perhaps the most important discovery in half a…”
BackgroundInfluentialWei, S., Tang, Y., Wang, F., Wang, Y., & Geng, X. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1216689 · Cited by 6
Karabanov, A., Ziemann, U., Hamada, M., George, M. S., Quartarone, A., Classen, J., Massimini, M., Rothwell, J., & Siebner, H. R. (2015) · Brain Stimulation · doi:10.1016/j.brs.2015.06.016 · Cited by 5
Gao, L., Wang, J., Liu, X., Wu, L., Ding, R., Han, X., Wang, X., Ma, H., Pan, J., Zhang, X., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-99587-4 · Cited by 6
Okamoto, N., Fujii, R., Chibaatar, E., Iino, C., Ikenouchi, A., & Yoshimura, R. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s541312 · Cited by 4
“49 While our findings are consistent with the hypothesis of altered neural plasticity in MDD, 50,51 the literature remains inconclusive.”
Transcription factors Lef1 and Rest stimulate recovery from depressive states
Yamamoto, H., Araki, S., Onodera, R., Go, Y., & Abe, K. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02259-0 · Cited by 7
“…applied this method to investigate changes in TF-activity in the brains of a mouse model for depression, mainly focusing on the prefrontal cortex (PFC), an area frequently affected in depression and implicated in both the manifestation of depression symptoms and the recovery process [18, 33 – 35].”
Carmellini, P., Pinzi, M., Rescalli, M. B., & Cuomo, A. (2025) · Brain Sciences · doi:10.3390/brainsci16010018 · Cited by 7
“…include AMPA receptor positive allosteric modulators (“ampakines”), which aim to enhance excitatory throughput and synaptic potentiation, and metabotropic glutamate receptor (mGlu) modulators, such as mGlu2/3 negative allosteric modulators, which can increase presynaptic glutamate release [67].”
Stereoselective, sex-dependent 5-HT2A receptor modulation of cortical plasticity by MDMA in mice
Gaines-Smith, M., Silverman, J. M., Fiorillo, M., Younkin, J., Moore, K., Maltman, J. L., Revenga, M. D. L. F., Wolstenholme, J. T., Glennon, R. A., Dukat, M., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-025-02313-x · Cited by 8
“Atrophy of frontal cortex neurons has been implicated in the pathophysiology of several psychiatric disorders [37, 38].”
Sherwani, M. K., Khan, J., Zainab, S. R., Mazhar, M. U., Ghazanfar, S., & Tipu, M. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153882 · Cited by 6
Prophylactic Effects of n-Acethylcysteine on Inflammation-induced Depression-like Behaviors in Mice
Wang, Z., Hu, Q., Tian, C., Wang, R., Jiao, Q., Chen, F., Wu, T., Wang, J., Zhu, Y., Liu, A., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.05.005 · Cited by 5
Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder
Liu, R., Liu, N., Ma, L., Liu, Y., Huang, Z., Peng, X., Zhuang, C., Niu, J., Yu, J., & Du, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01123-x · Cited by 8
“It plays a crucial role in maintaining normal neuronal development in the brain, closely linking to human learning, memory, and emotions [65, 66].”
5-HT1B receptor activation produces rapid antidepressant-like effects in rodents
Clark, E. A., Wang, L., Hanania, T., Kretschmannova, K., Bianchi, M., Jagger, E., Hu, T., Li, F., Gallero-Salas, Y., Koblan, K. S., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173917 · Cited by 5
Chen, X., Wei, K., Peng, S., Liu, N., He, L., Wu, B., Shi, M., & Lin, Y. Q. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03548-y · Cited by 7
Chen, Y., Yao, X., Wang, C., Zhuang, H., Xie, B., Sun, C., Wang, Z., Zhou, X., Luo, Y., Zhang, Y., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.035 · Cited by 5
Contó, M. B., Pautassi, R. M., & Camarini, R. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.04.015 · Cited by 4
Rech, T. D. S. T., Strelow, D. N., Krüger, L. D., Neto, J. S. S., Blödorn, G. B., Alves, D. A. C., Brüning, C. A., & Bortolatto, C. F. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02508-3 · Cited by 6
“Elevated glutamatergic activity in the hippocampus through NMDA receptors, along with associated alterations in hippocampal plasticity, is believed to contribute to the pathophysiology of MDD (Lander et al. 2020).”
InfluentialZhu, W., Zhang, W., Yang, F., Cai, M., Li, X., Xiang, Y., Xiang, J. Y., Yang, Y., & Cai, D.-F. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1108494 · Cited by 5
Gautier‐Stein, A., Vily‐Petit, J., Rajas, F., & Mithieux, G. (2023) · Biochimie · doi:10.1016/j.biochi.2023.11.012 · Cited by 5
Qian, X., Zhang, Y., & Tan, H.-J. (2023) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x231224528 · Cited by 8
“12 Interestingly, most antidepressants have been determined to produce effects within the synapse.”
BackgroundDeng, Y., Liang, X., Li, Y., Jiang, L. H., Wang, J., Tang, J., Li, J., Xie, Y., Xiao, K., Zhu, P., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109908 · Cited by 6
Bikri, S., Fath, N., Aboubi, M. E., Lamtai, M., Douae, B., & Aboussaleh, Y. (2024) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2024.2343974 · Cited by 7
“Dysregulation of synaptic plasticity is widely recognized as a contributing factor to the pathophysiology of depression [60].”
Yang, H., Chen, Y., Tao, Q., Shi, W., Tian, Y. Q., Wei, Y., Li, S., Zhang, Y., Han, S., & Cheng, J. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111052 · Cited by 6
Qiu, L., Chen, X., Fu, J., Chen, X., & Wang, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06035-0 · Cited by 13
“Furthermore, esketamine’s ability to increase gamma-aminobutyric acid (GABA) transmission and reduce the excitotoxic effects of glutamate contributes to its efficacy in alleviating depressive symptoms [26, 27].”
Neuronal TCF7L2 in Lateral Habenula Is Involved in Stress-Induced Depression
Li, X., Liu, X., Liu, J., Zhou, F., Li, Y., Zhao, Y., Yin, X., Shi, Y., & Shi, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212404 · Cited by 7
“Despite significant advances in understanding the neurobiological underpinnings of depression, the precise mechanisms that drive the onset and persistence of this disorder remain elusive [3,4].”
Elevated neuron specific enolase levels in post-traumatic stress disorder
Uysal, M., Ceylan, M. F., & Hesapçıoğlu, S. T. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05889-6 · Cited by 5
“…(HPA) regulation [2, 21, 22], resulting in damage to glucocorticoid signaling in the prefrontal cortex and hippocampus, increased neuroinflammation [2], decreased BDNF levels [7], astrocyte damage [7, 8], and extracellular glutamate accumulation due to impaired astrocytic uptake [6].”
Mei, Y.-X., Chen, H.-S., Cao, Q.-L., Lv, W., Liu, Y., Deng, S., Zhou, Q., Zhang, Z., Wang, F., Hu, Z., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03239-y · Cited by 11
“These fi ndings are corroborated by human postmortem studies, which show loss of synapses and lower expression of synapse-related genes in the PFC of patients with depression [3, 4].”
Perspectives on depression—past, present, futurea
Barchas, J. D., & Brody, B. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12773 · Cited by 9
Remodeling chromatin and synapses in depression
Duman, R. S. (2013) · Nature Medicine · doi:10.1038/nm.3125 · Cited by 6
Self-citationHisaoka‐Nakashima, K., Matsumoto, C., Azuma, H., Taki, S., Takebayashi, M., Nakata, Y., & Morioka, N. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00383 · Cited by 5
Lv, Y., Chen, P., Kuang, L., Han, Z., Solanki, B., Zhou, W., Tao, F., Chen, R., & Yao, Y. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147029 · Cited by 6
“Stress is an emotional state caused by dangerous or unexpected changes in the external environment [4, 5].”
BackgroundNiiyama, T., Kuroiwa, M., Yoshioka, Y., Kitahara, Y., Shuto, T., Kakuma, T., Ohta, K., Nakamura, K., Nishi, A., & Noda, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00268 · Cited by 5
“Depression is thought to be associated with neuronal atrophy including loss of synapses in the prefrontal cortex and hippocampus in humans and rodent chronic stress models, and alterations of spine synapse connectivity likely contribute to behavioral symptoms of depression (Duman and Aghajanian, 2012; Duman and Duman,…”
BackgroundHan, X.-M., Huang, F., Jiao, M., Liu, H., Zhao, Z., Zhan, H., & Guo, S. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00093 · Cited by 5
Bieler, M., Hussain, S., Daaland, E. S. B., Mirrione, M. M., Henn, F. A., & Davanger, S. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25155 · Cited by 7
“It has been hypothesized that changes in the relative concentration of proteins regulating synaptic efficacy are associated with neuropsychiatric disease such as major depressive disorder (Duman & Aghajanian, 2012; Kang et al., 2012).”
BackgroundAbdallah, C. G., & Mason, G. F. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01122-2 · Cited by 5
Rajkowska, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4_14 · Cited by 6
Jia, L., Jian, L., Jin, S. K., Manshu, Z., Yajie, J., & Yuhong, W. (2022) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2022.06.010 · Cited by 5
Confinement induces oxidative damage and synaptic dysfunction in mice
Li, N., Wang, H., Xin, S., Min, R., Zhang, Y., & Deng, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.999574 · Cited by 5
“Previous studies revealed that synaptic dysfunction contributed to pathological development of depression (Duman and Aghajanian, 2012).”
BackgroundSzopa, A., Herbet, M., Poleszak, E., Serefko, A., Czylkowska, A., Piątkowska‐Chmiel, I., Kasperek, K., Wróbel, A., Prewencka, P., & Szewczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814157 · Cited by 10
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
Trauma and Stressor-Related Disorders 2: Adjustment Disorders
Strain, J. J. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_17 · Cited by 6
Morozova, A. Y. (2013) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2013/4994 · Cited by 5
Liu, Y., Chen, C., Zhao, Y., Li, M., Gao, Y., Yan, B., Jing, Y., Zhang, B., & Li, J. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2025.107472 · Cited by 4
Xu, L., Cao, Y., Zhang, S., Du, L., Wang, W., Liu, J., Wang, D., Zhao, D., Cui, M., Jiang, S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111400 · Cited by 6
The cognitive neuroscience of ketamine in major depression
Costi, S., Wigg, C., Pulcu, E., Murphy, S. E., & Harmer, C. J. (2025) · Brain · doi:10.1093/brain/awaf242 · Cited by 49
“33,34 In animal models, ketamine re-stores synaptic plasticity and reverts the atrophy that follows chronic stress.”
Xu, H., Zhang, Z., Chen, G., Ge, M.-J., Yu, Z.-H., Shen, J.-X., Pan, C., Han, F., Zhu, X.-L., & Lu, Y.-P. (2025) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000845 · Cited by 6
Abnormal O-glycan sialylation in the mPFC contributes to depressive-like behaviors in male mice
Seo, Y., Song, I., Kim, K. J., Chang, B., Pradeep, P., Roh, W. S., Won, W., Joo, J., Kim, M., Jeong, J. C., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady2733 · Cited by 6
“Dysfunction in the PFC, including reduced synaptic plasticity and altered neuronal signaling, is commonly associated with depression ( 38 ).”
Zhang, Y., Zheng, Y., Xu, T., Wang, Q., Sang, T., Sheng, X., Fang, Y., & Chu, L. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110704 · Cited by 6
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.